For reduced risk of chronic disease and a better chance at a longer life, midlife weight loss may be helpful, a new study ...

The U.S. Food and Drug Administration has approved GSK's Nucala (mepolizumab) as an add-on maintenance treatment for adult ...

MD, CFPC, FCFP, Family Physician, discusses What is Chronic Obstructive Pulmonary Disease.

New tools, treatment options, and precision medicine developments are leading to better quality of life and survival for ...

Chronic obstructive pulmonary disease (COPD) affects millions of Americans, with new data from the National Center for Health Statistics showing the condition becomes increasingly common as people age ...

Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

Long-term oxygen therapy (LTOT) is linked to reduced exacerbations and hospitalizations in COPD, ILD, and pulmonary hypertension.

as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD). Nucala stands out as the only approved biologic that has been ...

Gerard Criner, MD, FACP, FACCP, MATINEE investigator, highlights trial results that showed reduced exacerbations and delayed disease progression in patients with eosinophilic chronic obstructive ...

and lifestyle changes Chronic obstructive pulmonary disease, commonly referred to as COPD, is a group of progressive lung diseases. An estimated 32 million people in the United States have COPD.

A BMJ Open Respiratory Research study finds women aged over 40 face a 50% higher risk of developing COPD than men—even ...

FRIDAY, May 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled ...